SCHEMBL20689484

SCHEMBL20689484

CCOC(=O)c1cnn2c(N(C)Cc3ccccc3)cc(-c3c[nH]c4ncc(Cl)cc34)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.45
▸ HSD17B10 Q99714 6/20 0.45
▸ HPGD P15428 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CASP1 P29466 3/20 0.42
▸ CASP7 P55210 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ MAPT P10636 4/20 0.40
▸ LMNA P02545 1/20 0.40
▸ JAK2 O60674 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ GAA P10253 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20689336 0.91 KDM4E (0.45) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL20688009 0.89 KDM4E (0.47) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL21961725 0.88 KDM4E (0.49) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL21948920 0.85 KDM4E (0.45) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL20697307 0.84 TYK2 (0.48) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL20697361 0.83 KDM4E (0.42) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL21948058 0.82 KDM4E (0.47) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL21960689 0.81 KDM4E (0.49) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL21964836 0.80 CDC7 (0.49) CDK2CCNA2JAK2PDPK1CDC7
SCHEMBL20688889 0.80 KDM4E (0.53) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 — — US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 — — US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 — — US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 — — US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 — — US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
WO-2019023468-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2019-01-31 — — WO disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 KDM4E 391/4885HSD17B10 2692/4885HPGD 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback